Home

 Accelerate Your Clinical Research Projects Clinical Trial Evaluation Approval Performances
Share

Approval Performances

Filters (0)
Apply filters

37-48 of 111 results

Clear filters
BP41072
Lymphome Phase III
  • 14.2 weeks
C2321008
Prostate Cancer Phase III
  • 11.4 weeks
  • 1st site activated in Canada
C2321008
Prostate Cancer Phase III
  • 11.6 weeks
C2321008
Prostate Cancer Phase III
  • 11.6 weeks
C2321008
Prostate Cancer Phase III
  • 10.2 weeks
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
  • 8.4 weeks
  • 1st site activated in Canada
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
  • 8.8 weeks
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
  • 14.8 weeks
C4551002
Breast Cancer Phase III
  • 9.4 weeks
  • 1st site activated in Canada and Canadian FPI
C4551002
Breast Cancer Phase III
  • 20.6 weeks
C4551002
Breast Cancer Phase III
  • 16.6 weeks
C4551002
Breast Cancer Phase III
  • 19.6 weeks
C4921003
Heart Failure Phase II
  • 12.2 weeks
C4921003
Heart Failure Phase II
  • 12.4 weeks
C4921003
Heart Failure Phase II
  • 14.4 weeks
CA071-1000
Prostate Cancer Phase III
  • 8.8 weeks
  • 1st site activated in Canada
CA071-1000
Prostate Cancer Phase III
  • 10.6 weeks
CA071-1000
Prostate Cancer Phase III
  • 12.8 weeks
CA071-1000
Prostate Cancer Phase III
  • 10.6 weeks
  • Canadian FPI
CA240-0030
Oncology (Metastatic Pancreatic Ductal Adenocarcinoma) Phase II/III
  • 10.4 weeks
  • 1st site activated in Canada
CA244-0001
Advanced Solid Tumors Phase I/II
  • 9.6 weeks
  • 1st site activated in Canada and 2nd site activated worldwide
CA244-0001
Advanced Solid Tumors Phase I/II
  • 12.4 weeks
  • 2nd site activated in Canada and 3rd site activated worldwide
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
  • 8 weeks
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
  • 11.6 weeks
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
  • 12 weeks
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
  • 16.4 weeks
  • 1st site activated in Canada
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
  • 17 weeks
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
  • 22 weeks
CAAA601A42101
Lung Cancer Phase I/II
  • 13.2 weeks
  • 1st site activated in Canada
CAAA601A42101
Lung Cancer Phase I/II
  • 14 weeks
CESP359A12101
Prostate Cancer Phase I
  • 9.8 weeks

Use the FAST TRACK Evaluation Service to Start Your Clinical Trials

Learn more Contact us